Comparison of the Bioavailability of Fenofibric Acid and Rosuvastatin From ABT-143 Relative to That From the Coadministration of ABT-335 (Fenofibric Acid) and Rosuvastatin Calcium

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00808678
First received: December 2, 2008
Last updated: September 27, 2012
Last verified: September 2012
  Purpose

The purpose of this study is to evaluate the safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.


Condition Intervention Phase
Healthy
Drug: ABT-143
Drug: ABT-335
Drug: rosuvastatin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To determine the safety and tolerability of ABT-143 vs (ABT-335 + rosuvastatin) in healthy adults [ Time Frame: 7 days ] [ Designated as safety issue: Yes ]
  • To determine the pharmacokinetic profile(s) for ABt-143 vs. (ABT-335 + rosuvastatin) in healthy adults [ Time Frame: 7 days ] [ Designated as safety issue: No ]

Enrollment: 90
Study Start Date: December 2008
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
ABT-143 capsules 20/135 mg
Drug: ABT-143
once, see arm description for more information
Other Name: ABT-143
Active Comparator: 2
ABT-335 135 mg and rosuvastatin 20 mg
Drug: ABT-335
once, see arm description for more information
Other Name: ABT-335
Drug: rosuvastatin
once, see arm description for more detail
Other Name: rosuvastatin

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. A condition of general good health
  2. BMI 19 to 29

Exclusion Criteria:

  1. Currently enrolled in another clinical study
  2. Females who are pregnant or breast-feeding
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00808678

Locations
United States, Florida
Site Reference ID/Investigator# 14762
Orlando, Florida, United States, 32809
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Torbjörn Lundström, MD AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00808678     History of Changes
Other Study ID Numbers: M10-662
Study First Received: December 2, 2008
Last Updated: September 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
Adverse Events

Additional relevant MeSH terms:
Fenofibric acid
Rosuvastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Lipid Regulating Agents
Therapeutic Uses
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on April 23, 2014